Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors
Frontiers in Oncology · 18.04.2023 · 13
DOI: 10.3389/fonc.2023.1147591 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Oncology, online erschienen am 18.04.2023. Verfasst von Maria Rasmussen und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cancer Research UK, Medical Research Council, Danish Cancer Society Research Center.
Abstract (Originalsprache)
Introduction
Lynch syndrome-associated cancer develops due to germline pathogenic variants in one of the mismatch repair (MMR) genes, MLH1 , MSH2 , MSH6 or PMS2 . Somatic second hits in tumors cause MMR deficiency, testing for which is used to screen for Lynch syndrome in colorectal cancer and to guide selection for immunotherapy. Both MMR protein immunohistochemistry and microsatellite instability (MSI) analysis can be used. However, concordance between methods can vary for different tumor types. Therefore, we aimed to compare methods of MMR deficiency testing in Lynch syndrome-associated urothelial cancers.
Methods
Ninety-seven urothelial (61 upper tract and 28 bladder) tumors diagnosed from 1980 to 2017 in carriers of Lynch syndrome-associated pathogenic MMR variants and their first-degree relatives (FDR) were analyzed by MMR protein immunohistochemistry, the MSI Analysis System v1.2 (Promega), and an amplicon sequencing-based MSI assay. Two sets of MSI markers were used in sequencing-based MSI analysis: a panel of 24 and 54 markers developed for colorectal cancer and blood MSI analysis, respectively.
Results
Among the 97 urothelial tumors, 86 (88.7%) showed immunohistochemical MMR loss and 68 were successfully analyzed by the Promega MSI assay, of which 48 (70.6%) were MSI-high and 20 (29.4%) were MSI-low/microsatellite stable. Seventy-two samples had sufficient DNA for the sequencing-based MSI assay, of which 55 (76.4%) and 61 (84.7%) scored as MSI-high using the 24-marker and 54-marker panels, respectively. The concordance between the MSI assays and immunohistochemistry was 70.6% (p = 0.003), 87.5% (p = 0.039), and 90.3% (p = 1.00) for the Promega assay, the 24-marker assay, and the 54-marker assay, respectively. Of the 11 tumors with retained MMR protein expression, four were MSI-low/MSI-high or MSI-high by the Promega assay or one of the sequencing-based assays.
Conclusion
Our results show that Lynch syndrome-associated urothelial cancers frequently had loss of MMR protein expression. The Promega MSI assay was significantly less sensitive, but the 54-marker sequencing-based MSI analysis showed no significant difference compared to immunohistochemistry. Data from this study alongside previous studies, suggest that universal MMR deficiency testing of newly diagnosed urothelial cancers, using immunohistochemistry and/or sequencing-based MSI analysis of sensitive markers, offer a potentially useful approach to identification of Lynch syndrome cases.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Clinical Research, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark.
- Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
- Center for Healthy Aging, Department of Cellular and Molecular Medicine, University of Copenhagen, Copenhagen, Denmark.
- Institute of Clinical Sciences, Division of Oncology and Pathology, Lund University, Lund, Sweden.
- Molecular Unit, Department of Pathology, Copenhagen University Hospital - Herlev and Gentofte, Copenhagen, Denmark.
- Biosciences Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom.
Förderung
- Cancer Research UK
- Medical Research Council
- Danish Cancer Society Research Center
Zitieren
APA
Rasmussen, M., Sowter, P., Gallon, R., Durhuus, J. A., Hayes, C., Andersen, O., Nilbert, M., Schejbel, L., Høgdall, E., Santibanez-Koref, M., Jackson, M. S., Burn, J., & Therkildsen, C. (2023). Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors. Frontiers in Oncology, 13. https://doi.org/10.3389/fonc.2023.1147591
Vancouver
Rasmussen M, Sowter P, Gallon R, Durhuus JA, Hayes C, Andersen O, et al. Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors. Frontiers in Oncology. 2023;13. doi:10.3389/fonc.2023.1147591
BibTeX
@article{Rasmussen2023,
author = {Rasmussen, Maria and Sowter, Peter and Gallon, Richard and Durhuus, Jon Ambæk and Hayes, Christine and Andersen, Ove and Nilbert, Mef and Schejbel, Lone and Høgdall, Estrid and Santibanez-Koref, Mauro and Jackson, Michael S and Burn, John and Therkildsen, Christina},
title = {Mismatch repair deficiency testing in Lynch syndrome-associated urothelial tumors},
journal = {Frontiers in Oncology},
year = {2023},
volume = {13},
doi = {10.3389/fonc.2023.1147591}
}
EUVIMED